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Abstract 31 
Streptococcus mutans harbours an intracellular, human DPP IV analogous enzyme Xaa-Pro 32 
dipeptidyl-peptidase (EC 3.4.14.11).  According to previous reports, an extracellular isozyme 33 
in S. gordonii and S. suis has been associated with virulence.  In a speculation that even an 34 
intracellular form may aid in virulence of S. mutans, we have tried to purify, characterize and 35 
evaluate enzyme inhibition by specific inhibitors. The native enzyme was partially purified 36 
by ion-exchange and gel filtration chromatography. Owing to low yield, the enzyme was 37 
overexpressed in Lactococcus lactis and purified by affinity chromatography. The 38 
recombinant enzyme (rSm-XPDAP) had a specific activity of 1,070 U/mg, while the Vmax 39 
and Km were 7 M min
-1
 and 89 ± 7M (n = 3), respectively. Serine protease inhibitor 40 
phenylmethane-sulphonyl-fluoride and DPP IV specific inhibitor Diprotin A proved to be 41 
active against rSm-XPDAP.  As a novel approach, the evaluation of anti-human DPP IV 42 
(AHD) drugs on rSm-XPDAP activity found saxagliptin to be effective to some extent (Ki = 43 
129 ± 16 M), which may  lead to the synthesis and development of a new class of 44 
antimicrobial agents.  45 
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Introduction 46 
Streptococcus mutans is one of the major etiological agents of dental caries and may 47 
opportunistically cause infective endocarditis (Nakano et al. 2010).  Genome study as well as 48 
proteolytic assays have shown the abundance of peptidases expressed by S. mutans 49 
(Cowman, Perrella and Fitzgerald 1975; Ajdić et al. 2002). Owing to its presence in the oral 50 
cavity, these peptidases may facilitate in utilizing salivary polypeptides as a reservoir of 51 
nutrition.  Aside from nutritional role, proteolysis play an integral role in cell regulation and 52 
alleviation of cellular stress, a condition commonly prevailing in the oral cavity (Jenal and 53 
Hengge-Aronis 2003). Hence, such proteases can be a suitable target for synthesis of new 54 
antimicrobials. 55 
The class of serine proteases includes several bacterial enzymes that endow pathogenic 56 
potential. Glutamyl endopeptidase, exfoliative toxin A in S. aureus, conserved heat shock 57 
protein DegP, IgA1 proteases, trepolisin produced by Treponema denticola, tripeptidyl 58 
peptidases, prolyl aminopeptidases, serine acyl transferases, Clp proteases are among the 59 
serine proteases well studied as possible therapeutic targets (Supuran, Scozzafava and 60 
Mastrolorenzo 2001). Xaa-Pro dipeptidyl aminopeptidase (XPDAP) (EC 3.4.14.11) is a 61 
narrow range serine protease, which cleaves oligopeptides with a penultimate proline residue 62 
from the N-terminus. Pioneering enzymatic studies on XPDAP from L. lactis had suggested 63 
an orthologous enzyme in streptococci, with an implication of this enzyme in pathogenecity 64 
(Rigolet et al. 2005). In evidence, extracellular XPDAP present in S. suis and S. gordonii was 65 
found to have a role in cellular invasion (Goldstein et al. 2001; Ge et al. 2009). Other than 66 
streptococci, deficiency of XPDAP in periodontal pathogen Porphyromonas gingivalis 67 
caused altered virulence, through lesser connective tissue destruction and less effective 68 
mobilization of inflammatory cells in a mouse abscess model (Yagishita et al. 2001). S. 69 
mutans embodies an intracellular XPDAP (Sm-XPDAP), which shows 50-60% identity 70 
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among other oral streptococcal species (Fig. 1).  Previous report on the aminopeptidase 71 
activity of this bacterium with a more predominating dipeptidyl peptidase activity has 72 
emphasized its importance in utilization of proline rich salivary peptides (Cowman and Baron 73 
1993, 1997). Additionally, a collagenolytic and caseinolytic activity may further substantiate 74 
the importance of Xaa-Pro dipeptidyl aminopeptidase as a virulence factor and nutritional 75 
necessity in S. mutans, respectively (Cowman, Perrella and Fitzgerald 1975; Rosengren and 76 
Winblad 1976). Overall, these may indicate the potency of Sm-XPDAP as a selective drug 77 
target.   78 
Dipeptidyl peptidase IV (DPP IV) (EC 3.4.14.5) is a XPDAP analogous enzyme found in 79 
mammals and has been a potent target for maintaining glucose homeostasis in Type II 80 
diabetic patients (Wang et al. 2012). Certain drugs namely saxagliptin, vildagliptin and 81 
sitagliptin are commonly used anti-human DPP IV (AHD) molecules by these patients 82 
(Green, Flatt and Bailey 2006). In a speculation that these drug molecules may show an 83 
inhibitory effect on S. mutans XPDAP (Sm-XPDAP) and thus serve as a template to develop 84 
novel molecules specific against this enzyme but not human DPP IV, the gene encoding the 85 
enzyme was cloned, purified, characterized and assayed for the inhibition of its activity by 86 
DPP IV specific inhibitor and AHD molecules. . 87 
Materials and Methods 88 
Microorganisms and growth conditions 89 
Streptococcus mutans UA159 (ATCC 700610) was used for protein purification and cloning 90 
purposes. Glycerol stock of S. mutans UA159 was used to grow an overnight culture in Brain 91 
Heart Infusion broth (BHI). All the incubations of S. mutans cultures were done at 37⁰C 92 
under 5% CO2 atmosphere (Cowman and Baron 1990). 93 
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NICE system (Nisin Controlled gene Expression system, Mobitech) was used for cloning of 94 
pepX gene from S. mutans into Lactococcus lactis NZ9000, provided with the kit. It was 95 
grown in M17 broth or agar at 30⁰C supplemented with 0.5% glucose and chloramphenicol 96 
(10 g/mL) as and when required. Electrocompetent cells of L. lactis were prepared in M17 97 
broth supplemented with 0.5% glucose, 2.5% glycine and 0.5M sucrose (Holo and Nes 1989). 98 
Partial purification of native Sm-XPDAP 99 
Preparation of cell extracts 100 
A secondary culture (16 L) was prepared and harvested at O.D600 of 0.8 (mid-log phase) by 101 
centrifugation at 8000×g for 15 minutes at 4⁰C. All the steps were performed at 4⁰C if not 102 
otherwise specified. The cell pellets were washed twice in 10mM phosphate buffer, pH 7.5. 103 
The washed cells (25mg), were resuspended in the same buffer for sonication with an 104 
ultrasonic homogenizer (Misonix Sonicator 3000), at 12 Watts with each pulse of 30 sec. for 105 
5 times and an intermittent pause of 1 min. The lysate was centrifuged at 8000×g for 15 106 
minutes to remove the cell debris. The supernatant containing the native enzyme was used for 107 
further purification of the protein.  108 
Partial purification of native protein 109 
The soluble extract was fractionated with ammonium sulphate, collecting the protein 110 
precipitate in the range 50 - 75% saturation by centrifugation at 12,000×g for 20 minutes. The 111 
pellet was then gently redissolved in Buffer A (20mM Tris HCl buffer, pH 8.2) and dialyzed 112 
against the same buffer overnight. The dialyzed crude extract was bound to pre equilibrated 113 
Q-Sepharose column (2.5 x 16 cm), Pharmacia (now GE Healthcare Bio-Sciences AB, 114 
Sweden). The proteins were eluted using a linear concentration gradient of NaCl, generated 115 
by using 200mL of Buffer A containing 0.55M NaCl with an equal volume of Buffer A at a 116 
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flow rate of 0.5mL/min. The active fractions were identified by spectrophotometric analysis 117 
at 280nm and by amidolysis in presence of Gly-Pro-p-nitroanilide (Gly-Pro-pNA). They were 118 
then pooled, concentrated by ultrafiltration and dialyzed against Buffer B (20mM Na-K 119 
phosphate buffer, pH = 7.4) to be passed through a Superose 12 (GE Healthcare Bio-Sciences 120 
AB, Sweden), equilibrated with the same buffer. Proteins were eluted using buffer B 121 
containing 0.1M KCl. Similarly, the active fractions from gel filtration were dialyzed against 122 
buffer C (20mM Tris HCl, pH = 7.5) and concentrated. A polyanion S1 column (1 x 10 cm) 123 
(GE Healthcare Bio-Sciences AB, Sweden), equilibrated with buffer C, was used to separate 124 
Sm-XPDAP from the above fraction. The column was eluted using a linear concentration 125 
gradient of NaCl (0.5M) in buffer C. The active fractions were dialyzed against buffer A, 126 
concentrated and stored at -20 °C until use.  127 
 128 
DNA extraction, cloning and protein expression  129 
DNA extraction and cloning 130 
Chromosomal DNA was extracted from an overnight culture of S. mutans using a Genome 131 
extraction kit (Sigma Aldrich). Primers DPP-F (5’-132 
AATCCATGGCCAAATATAATCAATACAGTTATATCGGTACTTCA-3’) and DPP-R 133 
(5’-134 
ATAGAGCTCTTAGTGGTGGTGGTGGTGGTGAGCAATGGGGATTTCGATAGTTGA-135 
3’) were designed with restriction sites NcoI and SacI in the forward and reverse primers 136 
respectively. In order to favour affinity chromatography of the resulting recombinant protein 137 
a tandem repeat complementary sequence of 6 Histidine residues (His tag) was incorporated 138 
in DPP-R before the SacI site. The amplified fragment containing the gene Sm-pepX (SMU 139 
_395) and plasmid pNZ8148 (NICE System) were restriction digested using NcoI & SacI at 140 
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37⁰C overnight under appropriate conditions. The digestion products were ligated at 16⁰C 141 
overnight using T4 DNA ligase and electroporated in L. lactis NZ9000 using a Gene Pulser 142 
(Biorad)  143 
L. lactis  electrocompetent cells were prepared as described by Holo and Nes (Holo and Nes 144 
1989). The transformants were confirmed by PCR using extracted fusion plasmids as 145 
template DNA and DPP-F and DPP-R as primers. A new set of primers pNZ8148 F-seq (5’-146 
CGGCTCTGATTAAATTCTGAAG-3’), pNZ8148 R-seq (5’-147 
CGTTTCAAGCCTTGGTTTTC-3’), pepX int1 (5’-CCAGTCCCTATCACCAAGGA-3’) 148 
and pepX int2 (5’-TGCGGAATCTGCTATTTCTTC-3’) were used to sequence the insert 149 
(service provided by GATC Biotech, Germany). 150 
Protein expression, SDS PAGE and purification by affinity chromatography. 151 
The NisR and NisK regulated protein expression in the bacterial clone was induced by 1 152 
ng/mL Nisin (NICE System - Nisin Controlled gene Expression system, Mobitech) for 3 153 
hours (OD600 = 0.4). One millilitre of induced culture pellet was resuspended in reducing dye 154 
containing β- mercaptoethanol, boiled for 10 minutes and then centrifuged at 12,000×g for 10 155 
minutes. The supernatant was subjected to a 12% SDS-polyacrylamide gel electrophoresis 156 
(SDS-PAGE) under standard conditions.  157 
An affinity chromatography mediated by His-tag facilitated the purification of recombinant 158 
protein. A batch culture (100 mL) was used to purify recombinant Sm-XPDAP (rSm-159 
XPDAP). The cells were harvested by centrifugation at 8000×g for 15 minutes, washed in 1X 160 
Native Purification buffer (NPB) (Invitrogen), followed by resuspension in the same buffer 161 
containing 1mg/mL of lysozyme and incubated at 37⁰C for 30minutes. The protoplast 162 
preparation was then disrupted by sonication at 9W for 30 s, 3 pulses each with an interval of 163 
1 minute in ice and the lysate was centrifuged at 8000×g for 15 minutes. A ProBond 164 
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Purification system (Invitrogen), under native conditions was used to purify rSm-XPDAP 165 
from the crude extract. The active fractions were pooled and analysed by SDS-PAGE. The 166 
eluted protein was dialyzed against 0.02M Tris- HCl buffer overnight and stored at -80⁰C in 167 
20% glycerol. The protein concentration in the enzyme preparations was determined by the 168 
Bradford method using bovine serum albumin to set up the standard calibration curve.  169 
Enzyme properties and kinetic studies 170 
Dipeptidyl peptidase IV assays (in-vitro) 171 
The assay was performed in 96 microtiter well plates in 0.02M Tris HCl buffer (pH 7.5) at 172 
37⁰C and the amount of p-nitroanilide released was quantified at 410 nm (Yogisha and 173 
Ravisha 2010). The Km and Vmax values of the purified recombinant Sm-XPDAP (rSm-174 
XPDAP) enzyme were determined in presence of various concentrations of Gly-Pro-pNA as 175 
the substrate, in the range of 25-400M. 176 
The effect of pH on the activity of purified recombinant enzyme was checked in the pH range 177 
of 4.5 – 9.5. Acetate buffer (pH 4.5 – 5.5), phosphate buffer (pH 5.6 – 7.4), Tris-HCl buffer 178 
(pH 7.5 – 8.5) and Glycine NaOH buffer (pH 8.6 – 9.5) were used to compare the enzyme 179 
activity. rSm-XPDAP in the presence of respective buffer, pre-equilibrated at room 180 
temperature was incubated at 37⁰C for 5 min after addition of 200 M substrate.  181 
The temperature dependence of the enzyme activity was determined in Glycine NaOH buffer 182 
pH 9.0, in the temperature range 5 - 50⁰C in presence of 200M of substrate. After 5 min 183 
incubation the reaction was stopped immediately by addition of 50 L acetic acid.  184 
The dependence of enzyme activity towards different metal ions were analyzed in presence of 185 
100M of Cu2+, Fe3+, Se, Mg2+, Ag, Mn2+, Zn2+, Co2+, Ca2+, Fe2+ in 0.02M buffer (pH = 7.5) 186 
and 200 M of substrate. Incubation was achieved at 37⁰C for 10 min. 187 
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In order to evaluate the stability of enzyme at -20⁰C and -80⁰C the enzyme was stored for a 188 
month, thawed and checked for its activity.  189 
All the readings were taken in triplicates and the basic statistical analyses such as standard 190 
deviation, relative standard deviation and unpaired student t-test were performed using MS-191 
Excel workbook. 192 
Effect of antidiabetic drugs and protease inhibitors 193 
The inhibition constants (Ki) of AHD drugs Sitagliptin, Vildagliptin and Saxagliptin 194 
(Selleckchem, USA) against rSm-XPDAP were determined using a Dixon plot (Dixon 1953) 195 
at various concentrations of drugs in 0.02M buffer (pH 7.5) in two series of substrate 196 
concentrations (150µM & 300µM). The concentration of enzyme was 29 mU per assay. 197 
Additionally the effect of some well known protease inhibitors, namely Iodoacetamide, p-198 
chloromercurobenzoate, o-Phenanthroline, Sodium Dodecyl Sulphate (SDS), 199 
Phenylmethanesulfonylfluoride (PMSF), EDTA and DPP IV specific inhibitor Diprotin A, 200 
was evaluated against rSm-XPDAP. 201 
Results and Discussion     202 
Partial purification of Native Sm-XPDAP 203 
In an attempt to purify Xaa-Pro dipeptidyl-peptidase from S. mutans, crude extract was 204 
obtained from 16L of batch culture grown till mid log phase. Detection of amidolytic activity 205 
against Gly-Pro-pNA confirmed the presence of Sm-XPDAP in the crude extract. Initially, 206 
batch binding of the enzyme to DEAE-Cellulose and CMC-cellulose failed, which might be 207 
due to weak electrostatic interactions of the protein with the resin at pH 7.5. An ammonium 208 
sulphate precipitation increased the purity fold of the enzyme, although the yield was 209 
drastically affected. In the subsequent steps, the passage of protein through Q-Sepharose, 210 
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Superose 12 and Polyanion S1 increased the specific activity of Sm-XPDAP (Table 1). 211 
Polyanion S1 increased the specific activity by 17-fold compared to the crude extract. Total 212 
protein amounts recovered was very low. As a matter of fact, SDS-PAGE analysis of 213 
polyanion S1 active eluate did not show a clear band after Coomassie staining, whereas silver 214 
staining showed a band of expected size (Supplementary Figure 1). Nevertheless, the 215 
preparation of partially purified native enzyme was used to determine reference biochemical 216 
parameters, useful for comparison to over-expressed recombinant Sm-XPDAP. 217 
Cloning and Purification of recombinant enzyme 218 
A 2,276 bp DNA fragment encodes Xaa-Pro dipeptidyl aminopeptidase (XPDAP) in S. 219 
mutans (Ajdić et al. 2002). An initial attempt to clone the gene fragment in an E. coli based 220 
pET28a system was successful, but the over-expressed protein in the soluble fraction was not 221 
active. Hence Lactococcus lactis NZ9000 (pepN::nisRnisK) was used to clone pepX 222 
(encoding Sm-XPDAP) in the pNZ8148 vector. On Sanger sequencing of the insert, 2 223 
mismatches (His106  Arg107 and Ile194  Val195) were found. These mutations are around 224 
the N-terminus end of the protein, which should not affect the enzyme activity or proper 225 
folding of the active site as judged by 3D computer modeling (data not shown). The sequence 226 
identity level of the Sm-XPDAP compared to the other homologous streptococcal enzymes is 227 
about 50%. Moreover, a comparative study of the active site of S. mutans enzyme with that of 228 
other streptococci, bacteria and mammals available in the MEROPS database (Rawlings et al. 229 
2014), revealed interesting differences in the Gly-X-Ser-X-X-Gly consensus motif shared by 230 
serine proteases. In Sm-XPDAP, there is sequence Gly-Lys-Ser-Tyr-Leu-Gly that maintains 231 
the central serine (Ser349), the first and last glycine residues of the consensus motif (Fig. 1, 232 
underlined sequence). Lysine (Lys348) is at the second position of the consensus, which is 233 
occupied by tryptophan in mammals and Gram-negative bacteria (Ogasawara et al. 2005) or 234 
by isoleucine or leucine in all other streptococci (Fig. 1). The presence of this amino acid is 235 
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noteworthy because a lysine is also found in Lactococcus lactis that is the only Gram-positive 236 
bacterial species for which the 3D X-ray structure of XPDAP has been resolved (Rigolet et 237 
al. 2005). This may help in obtaining more useful data from computer modelled Sm-XPDAP 238 
structure based on L. lactis XPDAP. Tyrosine at position 350 is shared among streptococci 239 
and L. lactis and is constantly found in the mammalian homologues, while Gram-negative 240 
bacteria, such as Sterotrophomonas maltophilia, Pseudomonas sp. and Porphyromonas 241 
gingivalis, have asparagine or phenylalanine at the same site (Ogasawara et al. 2005). At last 242 
Leu351 is peculiar of streptococci as it is not found in XPDAP (DPP IV) of other organisms 243 
where glycine is constantly present instead. Hence, in streptococci the consensus motif of 244 
XPDAP would be Gly-X-Ser-Tyr-Leu-Gly. 245 
A nisin mediated induction of the desired protein was achieved, which showed a distinct 246 
protein band of the expected size (Supplementary Figure 2). Moreover, a comparison of the 247 
enzyme activity of an induced and uninduced L. lactis culture showed a remarkable 248 
difference in the rate of substrate hydrolysis (Vinduced / Vuninduced = 17), further confirming that 249 
the over-expressed enzyme was active. A batch culture extract was then passed through 250 
affinity column. The eluate containing rSm-XPDAP was enzymatically active, pure and 251 
showed proper size by SDS-PAGE analysis (86 KDa, Fig.2).  252 
Enzymatic characterization of recombinant Sm-XPDAP  253 
The approximate Vmax and Km value of rSm-XPDAP were 7 M min
-1
 and 89 ± 7M (n = 3) 254 
respectively, the latter being very close to that obtained by the partially purified native 255 
enzyme (Km = 92 M). rSm-XPDAP was therefore used for the subsequent enzyme 256 
characterization study. High enzyme activity may aid in explaining low yield of Sm-XPDAP, 257 
which is sufficient to maintain physiological homeostasis in S. mutans. The Km of native 258 
enzyme was found lower than both the mammalian enzymes (human : Km = 0.2 - 0.66 mM; 259 
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porcine: Km = 0.27 mM) (Puschel, Mentlein and Heymann 1982; Caporale et al. 1985; 260 
Nakajima et al. 2008), and the Gram-positive bacterial species XPDAP from S. anginosus, S. 261 
suis and S. gordonii studied so far (Km = 0.56 mM, 0.26 mM and 0.38 mM 262 
respectively)(Goldstein et al. 2001; Fujimura et al. 2005; Jobin et al. 2005; Sharoyan et al. 263 
2006). It should be noted that lower Km value suggests higher specificity of Sm-XPDAP 264 
towards its substrate. Owing to the higher specificity and ease of purification of Sm-XDAP 265 
compared to the mammalian enzyme from tissues, this enzyme may find a potential  266 
biotechnological application  in food and dairy industry (Prothera and Klaire Labs 2010). On 267 
purification, the specific activity of rSm-XPDAP was 1,070 U/mg (1U of enzyme = 1µmole 268 
of pNA released per minute at 37°C and pH = 7.5). 269 
The optimum pH and temperature of rSm-XPDAP were similar to that of XPDAP in other 270 
streptococci (Mineyama and Saito 1991; Jobin et al. 2005). Although the optimum 271 
intracellular pH of S. mutans is 7.0 (Dashper and Reynolds 1992), the optimum pH of the 272 
recombinant enzyme was 9.0 (Fig. 3). The enzyme was quite active even at pH 7.5. 273 
Considering the intracellular pH of S. mutans, the enzyme characteristics were determined at 274 
pH 7.5. The optimum temperature lied in the range 30 - 35⁰C (Fig. 3). Among metal ions, 275 
Zn
2+
 showed about 50% inhibition of enzyme activity as also seen in S. gordonii XPDAP 276 
(Goldstein et al. 2001), whereas others had no notable effect on the recombinant enzyme 277 
(Table 2).  278 
The serine protease inhibitor phenylmethane-sulphonyl-fluoride (PMSF) and SDS strongly 279 
inhibited rSm-XPDAP activity. The sulphydryl group inhibitor iodoacetamide and p-chloro-280 
mercuro- benzoate did not show any enzyme inhibition. EDTA and o-phenanthroline, a 281 
metalloprotease inhibitor showed a significant inhibition (p = 0.0001 and 0.0034 respectively, 282 
n = 3, unpaired student t-test, two tailed). This may indicate that Sm-XPDAP is a 283 
metalloprotease (Table 2). 284 
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The recombinant enzyme did not lose much activity after storage at -80⁰C for 3 months (74% 285 
residual activity). It was quite stable even after repeated freeze and thaw at -20⁰C (66% 286 
residual activity). But a ten times diluted enzyme in Tris buffer was not stable after 24 hours 287 
at 4⁰C. 288 
DPP IV specific inhibition activity against rSm-XPDAP 289 
 290 
Like all other bacterial DPP IVs, DPP IV specific tripeptide Diprotin A was used as a 291 
reference inhibitor that showed a Ki of 16.7 µM. In view of the important role of Sm-XPDAP 292 
in S. mutans metabolism and its homology with the human enzyme, the effect of antidiabetic 293 
drugs on rSm-XPDAP was determined. Although sitagliptin and vildagliptin did not show 294 
any inhibition at 100 µM, saxagliptin was to some extent active and competitively inhibited 295 
rSm-XPDAP activity. An inhibition constant (Ki) of 129 ± 16 M was determined using a 296 
Dixon plot (Dixon 1953). The results were consistent with that observed in case of human 297 
DPP IV, where saxagliptin is most effective due to its strong interaction with two amino acids 298 
Ser630 and Glu205/206 compared to Ser630
 
in case of vildagliptin  (Wang et al. 2012). Similar 299 
interactions of saxagliptin at Ser349 and Glu393/396 of Sm-XPDAP may result in its higher 300 
inhibition. Inhibition of enzyme activity at 100µM of saxagliptin was significantly different 301 
from that of 50µM of the drug (p = 0.037, paired t-test).   Vildagliptin inhibited rSm-XPDAP 302 
by 47% at 900 µM, while 1mM of sitagliptin could exhibit only 37% enzyme inhibition 303 
(Table 3). At 500µM, both vildagliptin and sitagliptin showed slight inhibition of enzyme 304 
activity, although vildagliptin was more potent than the other (p<0.01, unpaired student t-305 
test).  Anticipating Sm-XPDAP as a potent antibacterial target, high inhibition constant (Ki) 306 
values of saxagliptin in an in vitro condition rules out to evaluate its antimicrobial efficacy, 307 
assuming that the MIC50 will be high.   This is a good indication as this drug is designed to 308 
act against human DPP IV. But, this may serve as a lead compound towards development of 309 
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molecules with lower inhibition constant against Sm-XPDAP and consequently as a potent 310 
antimicrobial. In addition, a higher effect by saxagliptin and vildagliptin may suggest that 311 
cyanopyrrolidide group can be a good starting scaffold to synthesize new molecules.   312 
In conclusion, Sm-XPDAP, an intracellular endopeptidase, is analogous to human DPP IV 313 
and is inhibited by antihuman DPP IV drug saxagliptin. Comparative study of XPDAP 314 
sequences revealed a unique sequence identity of the Sm-XPDAP in the consensus motif. 315 
These can lead to anticipate Sm-XPDAP as a novel antimicrobial target and consequently 316 
develop a new approach to treat caries. Future studies will be focusing on construction of Sm-317 
XPDAP knock out strain and development of new compounds inhibiting Sm-XPDAP. 318 
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Figure legends 401 
 402 
Figure 1. Sequence Alignment of Xaa-Pro dipeptidyl aminopeptidase of various oral bacteria. 403 
Sequences of various oral streptococci (S. mutans (MER022661), S. salivarius 404 
(MER188504), S. oralis (MER360252), S. mitis (MER360250), S. sanguinis (MER299432), 405 
S. gordonii (MER015080), S. pneumonia (MER014989), S. thermophilus (MER026289), S. 406 
suis (MER043202)),  and Lactococcus lactis (MER014202) obtained from MEROPS and 407 
aligned using the program CLUSTALW (Thompson, Higgins and Gibson 1994). The serine 408 
protease consensus sequence is underlined, serine of the catalytic site is indicated by an 409 
asterisk and the residues mutated in the recombinant protein by empty circles. 410 
 411 
Figure 2. SDS-PAGE analysis of active protein fraction after affinity chromatography. Lane 412 
1: Molecular marker, Lane 2: Purified rSm-XPDAP. 413 
 414 
Figure 3. Effect of pH and temperature on rSm-XPDAP activity. The plots represent mean ± 415 
SD of percentage residual activity from three independent experiments. 416 
 417 
 418 
